|
Volumn 31, Issue 3 SUPPL. 2, 1999, Pages 1S-6S
|
The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes following renal transplantation: Rationale for study design
a b c c a |
Author keywords
[No Author keywords available]
|
Indexed keywords
THYMOCYTE ANTIBODY;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CREATININE BLOOD LEVEL;
DRUG EFFICACY;
GRAFT SURVIVAL;
HUMAN;
IMMUNE RESPONSE;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY BIOPSY;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 0032949785
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(99)00092-5 Document Type: Conference Paper |
Times cited : (5)
|
References (42)
|